Literature DB >> 9872820

A community study of exhaled nitric oxide in healthy children.

P J Franklin1, R Taplin, S M Stick.   

Abstract

Exhaled nitric oxide (eNO) is elevated in patients with inflammatory pulmonary diseases and it has attracted increasing interest as a simple, noninvasive marker of airway inflammation. Little is known, however, about factors that might affect eNO in healthy subjects. We measured eNO in 157 healthy 7- to 13-yr-old children (mean 9.7 yr, 77 girls), with no history of respiratory tract disease, using a recently validated, single-breath technique. Measurements of eNO were obtained at driving (mouth) pressures of 10, 15, and 20 cm H2O and 3 eNO plateaux were achieved for each child at each pressure. Exhaled NO decreased with increasing pressure (increasing expiratory flow) (p < 0.001) and increased with age (p < 0.001). Concentrations were greater in children with a positive skin prick test (p < 0.0001). Geometric mean eNO levels were 7.2 ppb in children with no positive skin prick tests (n = 116), 10.9 ppb in children with one positive reaction (n = 24), and 20.1 ppb in children with two or more skin reactions (n = 17). Age and immunological reactions to common allergens are associated with increased eNO in children and should be controlled for in studies of eNO. The mechanisms responsible for these associations require further study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9872820     DOI: 10.1164/ajrccm.159.1.9804134

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms.

Authors:  J D Leuppi; S H Downs; S R Downie; G B Marks; C M Salome
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

2.  Effects of the indoor environment on the fraction of exhaled nitric oxide in school-aged children.

Authors:  Thomas A Kovesi; Robert E Dales
Journal:  Can Respir J       Date:  2009 May-Jun       Impact factor: 2.409

3.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

Review 4.  Exhaled nitric oxide: a test for diagnosis and control of asthma?

Authors:  Rohit Katial; Lora Stewart
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

5.  Exhaled nitric oxide: Not associated with asthma, symptoms, or spirometry in children with sickle cell anemia.

Authors:  Robyn T Cohen; Mark Rodeghier; Fenella J Kirkham; Carol L Rosen; Jane Kirkby; Michael R DeBaun; Robert C Strunk
Journal:  J Allergy Clin Immunol       Date:  2016-08-09       Impact factor: 10.793

6.  Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma.

Authors:  G Roberts; C Hurley; A Bush; G Lack
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

7.  Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath.

Authors:  C Lane; D Knight; S Burgess; P Franklin; F Horak; J Legg; A Moeller; S Stick
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

8.  Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma.

Authors:  L P Malmberg; A S Pelkonen; T Haahtela; M Turpeinen
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

9.  Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance.

Authors:  I Narang; R Ersu; N M Wilson; A Bush
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

10.  Exhaled nitric oxide in diagnosis and management of respiratory diseases.

Authors:  Abdullah A Abba
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.